DrugPatentWatch Database Preview
Tris Pharma Inc Company Profile
What is the competitive landscape for TRIS PHARMA INC, and when can generic versions of TRIS PHARMA INC drugs launch?
TRIS PHARMA INC has twenty-six approved drugs.
There are seven US patents protecting TRIS PHARMA INC drugs.
Summary for Tris Pharma Inc
| US Patents: | 7 |
| Tradenames: | 25 |
| Ingredients: | 24 |
| NDAs: | 26 |
| Drug Master File Entries: | 5 |
| Patent Litigation for Tris Pharma Inc: | See patent lawsuits for Tris Pharma Inc |
Drugs and US Patents for Tris Pharma Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | CLONIDINE | clonidine | SUSPENSION, EXTENDED RELEASE;ORAL | 022499-001 | Dec 3, 2009 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Tris Pharma Inc | DEXMETHYLPHENIDATE HYDROCHLORIDE | dexmethylphenidate hydrochloride | TABLET;ORAL | 207901-003 | Aug 26, 2016 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Tris Pharma Inc | GABAPENTIN | gabapentin | SOLUTION;ORAL | 091286-001 | Mar 14, 2016 | AA | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Tris Pharma Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,202,537 | Modified release formulations containing drug-ion exchange resin complexes | ➤ Sign Up |
| 9,549,989 | Modified release formulations containing drug-ion exchange resin complexes | ➤ Sign Up |
| 9,198,864 | Modified release formulations containing drug-ion exchange resin complexes | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Tris Pharma Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0709606 | ➤ Sign Up |
| Russian Federation | 2008140944 | ➤ Sign Up |
| Denmark | 2018160 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Tris Pharma Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 13/055 | Ireland | ➤ Sign Up | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| 00C/032 | Belgium | ➤ Sign Up | PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329 |
| 323 | Luxembourg | ➤ Sign Up | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
